Summary of COVID-19 ambavirumab studies
Studies
Meta Analysis
Hide extended summaries
RCT 837 non-hospitalized high-risk COVID-19 patients showing 78% reduction in hospitalization and death with BRII-196/BRII-198 (monoclonal antibodies). Study was terminated early. BRII-196/BRII-198 had fewer grade 3+ adverse events (3.8% vs 13.4%).
Oct 2021, Open Forum Infectious Diseases, https://academic.oup.com/ofid/article/8/Supplement_1/S807/6450927, https://c19p.org/evering
Retrospective 340 COVID-19 patients in China showing shorter length of hospital stay and faster viral clearance with BRII-196 plus BRII-198 monoclonal antibody treatment, especially when given early. The treatment did not show efficacy for improving clinical outcomes among severe or critical cases.
Apr 2024, BMC Pharmacology and Toxicology, https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-024-00753-7, https://c19p.org/yalan
354 patient ambavirumab late treatment RCT: 15% higher mortality (p=0.72) and 7% improved recovery (p=0.48).
RCT with 182 sotrovimab patients, 176 BRII-196+BRII-198 patients, and 178 control patients, median 8 days from symptom onset, showing no significant differences and terminated early due to futility.
Dec 2021, The Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00751-9/fulltext, https://c19p.org/self3am
1. Evering et al., Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
837 patient ambavirumab early treatment RCT: 89% lower mortality (p=0.02), 73% lower hospitalization (p<0.0001), and 79% lower combined mortality/hospitalization (p<0.0001).RCT 837 non-hospitalized high-risk COVID-19 patients showing 78% reduction in hospitalization and death with BRII-196/BRII-198 (monoclonal antibodies). Study was terminated early. BRII-196/BRII-198 had fewer grade 3+ adverse events (3.8% vs 13.4%).
Oct 2021, Open Forum Infectious Diseases, https://academic.oup.com/ofid/article/8/Supplement_1/S807/6450927, https://c19p.org/evering
2. Yalan et al., Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study
340 patient ambavirumab late treatment study: 71% higher mortality (p=0.35), 8% higher ICU admission (p=0.8), 8% shorter hospitalization (p=0.004), and 7% faster viral clearance (p=0.004).Retrospective 340 COVID-19 patients in China showing shorter length of hospital stay and faster viral clearance with BRII-196 plus BRII-198 monoclonal antibody treatment, especially when given early. The treatment did not show efficacy for improving clinical outcomes among severe or critical cases.
Apr 2024, BMC Pharmacology and Toxicology, https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-024-00753-7, https://c19p.org/yalan
354 patient ambavirumab late treatment RCT: 15% higher mortality (p=0.72) and 7% improved recovery (p=0.48).
RCT with 182 sotrovimab patients, 176 BRII-196+BRII-198 patients, and 178 control patients, median 8 days from symptom onset, showing no significant differences and terminated early due to futility.
Dec 2021, The Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00751-9/fulltext, https://c19p.org/self3am
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.